Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

New Oxford start-up is established to develop novel therapeutics based on the expertise of the Davis and Cornall groups at MRC HIU.

Load More

Similar stories

New bone marrow model offers scalable platform for next-generation drug discovery

Researchers at the MRC Weatherall Institute of Molecular Medicine have developed the first combined human bone and bone marrow organoid platform capable of modelling long-term blood and immune cell production in a fully human 3D system.